Clinical Indications

Monitoring trough levels of voriconazole is suggested in
patients with impaired liver function, patients with
pharmacogenomics polymorphisms associated with lower metabolism of
voriconazole (e.g. genotypes CYP2C19*2 and CYP2C19*3), and in
patients taking other medications that affect CYP2C19 activity.
Additionally, results may be clinically useful to determine if
current dosing levels have achieved adequate therapeutic
concentrations when treating at-risk patients prophylactically or
when treating patients with invasive fungal infections. Results may
also be used to evaluate reasons for therapeutic failure due to
suboptimal drug levels or for toxicity potentially attributable to
voriconazole.